We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Provid Announces National Cancer Institute Contract
News

Provid Announces National Cancer Institute Contract

Provid Announces National Cancer Institute Contract
News

Provid Announces National Cancer Institute Contract

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Provid Announces National Cancer Institute Contract "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Provid Pharmaceuticals Inc. has announced the award of a $750,000 phase II SBIR contract by the National Cancer Institute.

The NCI and Provid will collaborate on a number of oncology targets over the next two years.

Provid will apply its hypothesis-driven drug discovery chemistry to translate the assay hits into viable drug candidate leads for applications in cancer therapy.

These projects emerged from the efforts of the Developmental Therapeutics Program Screening Technologies Branch at NCI, where small molecule assay hits have been identified and are ready for medicinal chemistry validation and optimization.

Dr. Gary Olson, Provid CEO, discussed the contract, “We are excited about the expansion of Provid's role with the NCI to help discover drugs for cancer therapeutics, and with the opportunity to collaborate with the scientists who have uncovered the new research targets.”

“The program is a great opportunity for Provid, and we value the confidence that the NCI has placed in us.”

Advertisement